Metronidazole and tinidazole are the primary agents used for treatment of trichomoniasis, with standard regimens consisting of either a single 2 g dose or multidose therapy administered orally. Intravenous (IV) administration is noted as a potential alternative route when oral therapy is not feasible; however, specific IV dosing strategies or the clinical circumstances under which IV use should be employed are not described. [1], [2]
A 2004 narrative review on the microbiology, pharmacology, and treatment of Trichomonas vaginalis infection describes metronidazole as the primary systemic therapy, typically administered as oral single-dose or multidose regimens. Within this discussion, IV administration is noted, including doses of 500 mg to 2 g infused over approximately 20 minutes, with reported cure rates of 85% to 95% for both oral and IV regimens; however, these IV dosing details are derived from older referenced literature rather than contemporary treatment data. [3], [4]
Studies describe IV use of metronidazole within desensitization protocols. IV metronidazole has been administered using incremental dosing at 15 to 20 minute intervals, beginning at 0.005 mg and increasing stepwise (0.005 mg, 0.015 mg, 0.05 mg, 0.15 mg, 0.5 mg, 1.5 mg, 5 mg, 15 mg, 30 mg, 60 mg, 125 mg, 250 mg, 500 mg) to a final cumulative dose of 2 g, with reported clinical and microbiologic cure following completion of therapy. Importantly, these protocols involve gradual dose increases under close monitoring rather than administration of a single 2 g dose. [5], [6]
Although not specific to an intravenous single dose for trichomoniasis, available evidence from oral regimens and pharmacokinetic data may provide relevant context. A randomized trial demonstrated that a single 2 g oral dose resulted in higher rates of persistent infection compared with multidose therapy (19% vs 11%; risk ratio [RR] 0.55), and a meta-analysis found treatment failure was approximately 1.8 to 1.9 times more likely with single-dose therapy. Of note, metronidazole administered orally or intravenously has a bioavailability of approximately 93% to 100% and a half-life of approximately 8.7 hours with linear elimination. A single 2 g dose achieves concentrations above the minimum lethal concentration for up to 24 to 48 hours, followed by declining concentrations, whereas multidose regimens maintain concentrations above this threshold with each subsequent dose; however, these data are derived from in vitro pharmacodynamic studies and do not evaluate clinical outcomes for IV use. [7], [8], [9]